Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Methodological issues in negative symptom trials.

Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RS.

Schizophr Bull. 2011 Mar;37(2):250-4. doi: 10.1093/schbul/sbq161. Epub 2011 Jan 26.

2.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
3.

New pharmacotherapeutic modalities for negative symptoms in psychosis.

Lindenmayer JP.

Acta Psychiatr Scand Suppl. 1995;388:15-9. Review.

PMID:
7541598
4.

The negative component in schizophrenia.

Möller HJ.

Acta Psychiatr Scand Suppl. 1995;388:11-4. Review.

PMID:
7541597
5.

Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits.

Schooler NR.

Acta Psychiatr Scand Suppl. 1994;380:21-6. Review.

PMID:
7914043
6.

Algorithm for the treatment of negative symptoms in chronic schizophrenia.

Tsutsumi T, Uchimura H.

Psychiatry Clin Neurosci. 1999 Oct;53 Suppl:S15-7. Review.

7.

New drugs for the treatment of schizophrenic patients.

Fleischhacker WW.

Acta Psychiatr Scand Suppl. 1995;388:24-30. Review.

PMID:
7604735
8.
9.

Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia.

Nasrallah HA, Tandon R.

J Clin Psychiatry. 2002;63 Suppl 13:12-20. Review.

10.

Principal components and further possibilities with the PANSS.

von Knorring L, Lindström E.

Acta Psychiatr Scand Suppl. 1995;388:5-10. Review.

PMID:
7541600
11.

Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials.

Leucht S, Kissling W, McGrath J.

J Clin Psychiatry. 2004 Feb;65(2):177-86. Review.

PMID:
15003070
12.
13.

Assessing negative symptoms and extrapyramidal symptoms in schizophrenia: workshop report.

Kane JM, Dauphinais D, Barnes TR, Adler LA, Rifkin A.

Psychopharmacol Bull. 1993;29(1):45-9. Review. No abstract available.

PMID:
8104351
14.

The treatment of negative symptoms: pharmacological and methodological issues.

Carpenter WT Jr.

Br J Psychiatry Suppl. 1996 May;(29):17-22. Review. No abstract available.

PMID:
8733819
15.

[New chemotherapy approaches to psychoses].

Olié JP, Baylé FJ.

Encephale. 1997 Apr;23 Spec No 2:2-9. Review. French.

PMID:
9273302
16.

An industry perspective on the NIMH consensus statement on negative symptoms.

Alphs L.

Schizophr Bull. 2006 Apr;32(2):225-30. Epub 2006 Feb 9.

17.
18.

Novel antipsychotics and negative symptoms.

Möller HJ.

Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S43-7. Review.

PMID:
9690970
19.

Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.

Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, Kinon B, Leucht S, Lindenmayer JP, Malhotra AK, Stauffer V, Umbricht D, Wesnes K, Kapur S, Rabinowitz J.

Schizophr Res. 2013 Nov;150(2-3):328-33. doi: 10.1016/j.schres.2013.07.058. Epub 2013 Sep 9. Review.

PMID:
24028744
20.

Definitions of response and remission in schizophrenia: recommendations for their use and their presentation.

Leucht S, Davis JM, Engel RR, Kissling W, Kane JM.

Acta Psychiatr Scand Suppl. 2009;(438):7-14. doi: 10.1111/j.1600-0447.2008.01308.x. Review. Erratum in: Acta Psychiatr Scand Suppl. 2011 Jul;124(1):82.

PMID:
19132961

Supplemental Content

Support Center